Results 71 to 80 of about 65,267 (260)
Biomarkers in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is currently the third most frequent form of malignancy. The role of biomarkers in the diagnostic and therapeutic strategy of cancer is constantly expanding. Translational research is already changing paradigms in tumours encompassing from early diagnosis to precision medicine in advanced disease.
J. Gallego +4 more
openaire +3 more sources
Early Radiation Therapy Response Assessment Using Multi‐Scale Photoacoustic Imaging
Tomographic and mesoscopic photoacoustics capture intratumoural features of radioresistance and response. ABSTRACT There is a critical unmet clinical need to identify biomarkers that predict and detect radiation therapy (RT) response in cancer. Using the unique capabilities of multi‐scale photoacoustic imaging (PAI) to depict tumor oxygenation and ...
Thierry L. Lefebvre +12 more
wiley +1 more source
Emerging concepts in the management of pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma is characterised by poor oncological outcomes with curative treatment only possible for a minority. Symptoms are dependent on the stage of the disease and location within the pancreas with constitutional decline often ...
Sanket Srinivasa, Rowan Parks
doaj +1 more source
Consumed by Abdominal Distention
Arthritis Care &Research, EarlyView.
Abimbola Fadairo‐Azinge +3 more
wiley +1 more source
Lactylation‐Driven YTHDC1 Alleviates MASLD by Suppressing PTPN22‐Mediated Dephosphorylation of NLRP3
In MASLD, YTHDC1 undergoes increased lactylation and ubiquitination, reducing its expression. AARS1 mediates lactylation at lysine 565, while disrupted binding to LDHA further promotes lactylation, suppressing YTHDC1. This downregulation enhances PTPN22 mRNA stability, leading to NLRP3 dephosphorylation and activation, which exacerbates inflammation ...
Feng Zhang +16 more
wiley +1 more source
Imaging for pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide due to its aggressiveness and the challenge to early diagnosis. Complete surgical resection is the only curative option, but fewer than 20% of patients have potentially resectable disease at the time of the diagnosis.
Natally, Horvat +4 more
openaire +2 more sources
Gemcitabine is a common first-line chemotherapy agent, but gemcitabine resistance is a clinical challenge for pancreatic ductal adenocarcinoma patients.
Hao Yu +5 more
doaj +1 more source
This research identified cardiac amyloid pathology, neurotrophic factor depletion, and reduced myocardial nerve function in a transgenic model of cerebral amyloidosis (Tg2576), Aβ‐challenged cardiomyocytes, and in human AD heart tissue. These findings carry significant diagnostic and therapeutic implications, emphasizing the role of neuro‐signaling ...
Andrea Elia +6 more
wiley +1 more source
Background The perioperative factors predicting or influencing early pancreatic ductal adenocarcinoma recurrence are unclear. This study attempted to identify the predictive factors for early pancreatic ductal adenocarcinoma recurrence post ...
Hironobu Suto +9 more
doaj +1 more source
This study reveals that m6A regulators cooperatively upregulate BGN in melanoma, promoting malignancy. Within the tumor microenvironment, CAFs show highest BGN expression. The BGN/MDK axis mediates cancer‐stroma crosstalk, driving normal fibroblast (NF) activation and enhancing the pro‐tumor effect of CAFs, highlighting a promising therapeutic target ...
Hao‐ze Shi +16 more
wiley +1 more source

